N4 Pharma (N4P) AI Stock Analysis

• Market Cap: £4.16M
• Dividend Yield: N/A
• Average Volume (3M): 552.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 832,280,330
• 10 Day Avg. Volume: 400,768
• 30 Day Avg. Volume: 552,755
• PEG Ratio: 0.04
• Price to Book (P/B): 2.76
• Price to Sales (P/S): 245.40
• P/FCF Ratio: -1.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: 0.50p ▼(-16.00% Downside)

The score is primarily held back by weak financial performance—persistent losses, ongoing cash burn, and shrinking equity—despite the benefit of having no debt. Technicals also point to a downtrend (negative MACD and price below key moving averages), while valuation is constrained by negative earnings and no dividend support.

N4 Pharma Business Overview & Revenue Model

Company Description

N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

How the Company Makes Money

N4 Pharma Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.69K	7.28K	1.95K	0.00	0.00	0.00
Gross Profit	0.00	7.28K	1.95K	0.00	0.00	0.00
EBITDA	-470.22K	-1.22M	-1.33M	-1.19M	-1.84M	-1.56M
Net Income	-498.55K	-1.06M	-1.27M	-1.03M	-1.54M	-1.30M
Balance Sheet
Total Assets	1.85M	775.77K	1.28M	2.17M	2.34M	3.83M
Cash, Cash Equivalents and Short-Term Investments	1.73M	625.97K	1.03M	1.92M	1.78M	3.56M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	78.37K	124.37K	81.73K	77.89K	212.73K	169.08K
Stockholders Equity	1.77M	647.65K	1.13M	2.09M	2.13M	3.66M
Cash Flow
Free Cash Flow	-444.37K	-971.50K	-1.21M	-828.26K	-1.77M	-1.38M
Operating Cash Flow	-444.37K	-971.50K	-1.21M	-828.26K	-1.77M	-1.38M
Investing Cash Flow	0.00	0.00	781.00	0.00	0.00	0.00
Financing Cash Flow	1.55M	570.36K	315.90K	963.77K	677.00	3.97M

N4 Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£73.52M	24.33	3.62%	―	1.44%	359.79%
STX	63 Neutral	£111.49M	-5.65	-396.71%	―	93.48%	51.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PXS	51 Neutral	£22.87M	-32.50	-51.21%	―	61.13%	33.33%
N4P	42 Neutral	£4.16M	-2.08	-73.08%	―	―	―
CHLL	42 Neutral	£4.05M	―	―	―	―	―

N4 Pharma Corporate Events

N4 Pharma Advances Nuvec® Platform with Strategic Collaborations and Patent Strengthening

N4 Pharma has provided an operational update highlighting its collaboration with the University of Strathclyde, which is progressing well towards key studies in 2026. The company is focusing on demonstrating the competitive advantages of its Nuvec® nanoparticles over lipid nanoparticles, particularly in terms of stability, which is crucial for its N4 101 anti-inflammatory product and potential partnerships. Recent achievements include successful preclinical demonstrations of oral delivery and efficacy in inflammatory bowel disease and non-small cell lung cancer models. The company anticipates a strong flow of data-driven news and has strengthened its intellectual property position with new patent filings.

N4 Pharma Advances Nuvec® Gene Delivery System with Key Collaborations and Patent Strengthening

N4 Pharma has announced significant progress in its collaboration with the University of Strathclyde, focusing on the development of its Nuvec® gene delivery system. The company is working towards key studies in 2026 to demonstrate Nuvec®’s benefits over lipid nanoparticles, particularly in stability and targeting capabilities. Recent achievements include successful preclinical demonstrations in inflammatory bowel disease and non-small cell lung cancer, positioning Nuvec® as a competitive alternative in RNA therapeutic delivery. The company has also strengthened its intellectual property portfolio with new patent filings, enhancing its market position and potential for future partnerships.